ICC panel rules in cancer treatment dispute
An Austrian pharmaceuticals company has reportedly prevailed in a €2 billion ICC dispute with a Taiwanese partner that sought to end their agreement to develop and market a blood cancer drug.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10